Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Avi Kapoor

These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results

Crypto,Trader,Investor,Broker,Using,Smartphone,App,Analyzing,Financial,Data

Viridian Therapeutics, Inc. (NASDAQ:VRDN) reported upbeat results for the second quarter on Wednesday.

The company posted quarterly losses of $(1.00) per share which beat the analyst consensus estimate of $(1.02) per share. The company reported quarterly sales of $75.000 thousand which beat the analyst consensus estimate of $43.643 thousand.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.